Benevenuto-de-Andrade BA, León JE, Carlos R,
Delgado-Azañero W, Mosqueda-Taylor A, Paes-de-Almeida O. Immunohistochemical expression
of Skp2 protein in oral nevi
and melanoma. Med Oral Patol Oral Cir Bucal. 2013 May 1;18
(3):e388-91.
doi:10.4317/medoral.18781
|
1. Li W, Sanki A, Karim
RZ, Thompson JF, Soon Lee C, Zhuang L, et al. The
role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology. 2006;38:287-301. |
|
|
|
|
|
2. Penin RM, Fernandez-Figueras MT, Puig L, Rex J, Ferrandiz C, Ariza A.
Over-expression of p45(SKP2) in Kaposi's sarcoma correlates with higher tumor
stage and extracutaneous involvement but is not
directly related to p27(KIP1) down-regulation. Mod Pathol.
2002;15:1227-35. |
|
|
|
|
|
3. Li Q, Murphy M, Ross J, Sheehan C, Carlson JA.
Skp2 and p27kip1 expression in melanocytic nevi and
melanoma: an inverse relationship. J Cutan Pathol. 2004;31:633-42. |
|
|
|
|
|
4. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated
degradation of the CDK inhibitor p27. Nat Cell Biol. 1999;1:193-9. |
|
|
|
|
|
5. Sutterlüty H, Chatelain E, Marti A, Wirbelauer
C, Senften M, Müller U,
et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent
cells. Nat Cell Biol. 1999;1:207-14. |
|
|
|
|
|
6. Lim MS, Adamson A, Lin Z, Perez-Ordonez B, Jordan
RC, Tripp S, et al. Expression of Skp2, a p27(Kip1) ubiquitin
ligase, in malignant lymphoma: correlation with
p27(Kip1) and proliferation index. Blood. 2002;100:2950-6. |
|
|
|
|
|
7. Kudo Y, Kitajima S, Sato S, Miyauchi M,
Ogawa I, Takata T. High expression
of S-phase kinase-interacting protein 2, human
F-box protein, correlates with poor prognosis in oral squamous
cell carcinomas. Cancer Res. 2001;61:7044-7. |
|
|
|
|
|
8. Oliveira AM, Okuno SH, Nascimento AG, Lloyd RV. Skp2 protein expression in soft
tissue sarcomas. J Clin Oncol. 2003;21:722-7. |
|
|
|
|
|
9. Woenckhaus C, Maile S, Uffmann S, Bansemir M, Dittberner T, Poetsch M, et al. Expression of Skp2 and p27KIP1 in naevi and malignant melanoma of the skin and its relation
to clinical outcome. Histol Histopathol. 2005;20:501-8. |
|
|
|
|
|
10. Prasad ML, Patel SG, Huvos
AG, Shah JP, Busam KJ. Primary mucosal melanoma of
the head and neck: a proposal for microstaging
localized, Stage I (lymph node-negative) tumors. Cancer. 2004;100:1657-64. |
|
|
|
|
|
11. Rose AE, Wang G, Hanniford
D, Monni S, Tu T, Shapiro
RL, et al. Clinical relevance of SKP2 alterations in metastatic melanoma.
Pigment Cell Melanoma Res. 2011;24:197-206. |
|
|
|
|
|
12. Chen G, Cheng Y, Zhang Z, Martinka
M, Li G. Cytoplasmic Skp2 expression is increased
in human melanoma and correlated with patient survival. PLoS
One. 2011;6:e17578. |
|
|
|
|
|
13. Alonso
SR, Ortiz P, Pollán M, Pérez-Gómez B, Sánchez L,
Acu-a MJ, et al. Progression in cutaneous
malignant melanoma is associated with distinct expression profiles: a tissue
microarray-based study. Am J Pathol. 2004;164:193-203. |
|
|
|
|
|
14. Ben-Izhak O, Lahav-Baratz S, Meretyk S, Ben-Eliezer S, Sabo E, Dirnfeld M,
et al. Inverse relationship between Skp2 ubiquitin ligase and the cyclin dependent
kinase inhibitor p27Kip1 in prostate cancer. J Urol.
2003;170:241-5. |
|
|
|
|
|
15. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, et al.
Skp2 is oncogenic and overexpressed
in human cancers. Proc Natl Acad
Sci U S A. 2001;98:5043-8. |
|
|
|
|
|
16. Hershko D, Bornstein
G, Ben-Izhak O, Carrano
A, Pagano M, Krausz MM,
et al. Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2
in colorectal carcinomas. Cancer. 2001;91:1745-51. |
|
|
|
|
|
17. Shim EH, Johnson L, Noh HL, Kim YJ, Sun H, Zeiss C, et al. Expression of
the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma
in the mouse prostate. Cancer Res. 2003;63:1583-8. |
|
|
|
|